Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tiny Mabion Races Big Pharma To EU Rituximab Market

Executive Summary

Poland’s biotech Mabion is racing to the European biosimilar market with a biosimilar rituximab, but is up against multinational biosimilar companies like Sandoz and South Korea’s Celltrion, and will likely need a strong commercialization partner outside its home market.

You may also be interested in...



Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing

Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.

Ten Years On, Access To Biosimilars Still Patchy in EU

April saw the 10th anniversary of the first biosimilar approval in Europe –Sandoz International GMBH's Omnitrope (somatropin) – which was launched in 2006. But a decade on, even with 20 biosimilar products now available and many more to come as big biological drugs lose their patent protection, there are still significant barriers to biosimilar penetration and wide variations in patient access across the EU that need to be addressed.

Taking On The Big Guns: Life As A Boutique Biosimilar Developer

MAbxience, a biosimilar R&D company founded in 2009 as the biotechnology arm of CHEMO group, has opened a new manufacturing plant in Leon, Spain at which it hopes to produce up to six new monoclonal antibody biosimilars for its target markets of Europe and Latin America.

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel